Summary & Overview
HCPCS C9458: Florbetaben F18 PET Amyloid Imaging
HCPCS Level II code C9458 denotes a unit dose of florbetaben F18 for diagnostic PET imaging to assess cerebral beta-amyloid deposition. This radiopharmaceutical is clinically important for evaluation of patients with cognitive impairment when amyloid imaging is indicated; it informs diagnostic workups and may affect downstream care pathways. Nationally, PET amyloid agents are notable for their specialized handling, limited supply chain considerations, and payer coverage variability.
Key payers discussed include Medicare, Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. Readers will find an overview of coverage and reimbursement considerations across major national payers, typical sites of service where the agent is administered, and clinical context for use in amyloid PET imaging. The publication also outlines benchmarks for utilization and billing practice, recent policy updates affecting radiopharmaceuticals, and factors payers consider when authorizing amyloid PET studies.
The analysis is intended to help billing managers, radiology and nuclear medicine departments, and policy staff understand coding conventions, payer patterns, and operational considerations tied to C9458. Data not available in the input.
Billing Code Overview
HCPCS Level II code C9458 is described as Florbetaben F18, diagnostic, per study dose, up to 8.1 millicuries. This code represents a radiopharmaceutical diagnostic agent used in positron emission tomography (PET) imaging to detect beta-amyloid plaque in the brain.
-
Service type: Diagnostic radiopharmaceutical administration for PET imaging
-
Typical site of service: Outpatient imaging centers and hospital outpatient departments where PET brain imaging is performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an older adult referred by a neurologist for PET brain imaging to evaluate suspected Alzheimer disease or other neurocognitive disorder. The patient presents to an outpatient imaging center or hospital nuclear medicine department after a clinical evaluation noting progressive memory loss, impaired executive function, or atypical cognitive decline. The clinical workflow includes pre-authorization and scheduling, confirmation of patient identity and informed consent, screening for allergies and pregnancy, IV access placement, radiotracer preparation and quality check, administration of C9458 (florbetaben F18) per study dose (up to 8.1 millicuries), uptake period per protocol, PET/CT or PET acquisition of the brain by a nuclear medicine technologist, image reconstruction and attenuation correction (often using low-dose CT), interpretation by a nuclear medicine physician or neuroradiologist, and report generation describing tracer cortical uptake consistent with amyloid deposition or its absence. Typical sites of service are outpatient imaging centers, hospital outpatient departments, and ambulatory surgical centers with PET capability. The common clinical indication is detection or exclusion of cerebral beta-amyloid in patients with cognitive impairment to support diagnosis and management decisions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician interpretation of the PET study separate from the technical component. |